Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series

Maria Espositoa Department of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyCorrespondence[email protected] [email protected]

Alessandro Giuntab Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy

Ester Del Ducab Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy

Valeria Manfredab Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy

Alfonso Troisic Department of Systems Medicine, International Medical School, University of Rome “Tor Vergata”, Rome, Italy

Luca Bianchib Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy

Maria Concetta Fargnolia Department of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

show all

Click to increase image sizeClick to decrease image size

Declaration of interest

The contents of the paper and the opinions expressed within are those of the authors, and it was the decision of the authors to submit the manuscript for publication.

Maria Esposito has served as a consultant, speaker and board member for Novartis.

Luca Bianchi has served as a consultant, speaker and board member for Novartis.

Maria Concetta Fargnoli has served as a consultant, speaker and board member for Novartis.

A reviewer on this manuscript has disclosed that they have had support from Novartis as well as from Abbvie, Celgene, Janssen, Leo, Lilly, Ortho and Sun. Another reviewer has disclosed that they are an employee of Mount Sinai and have received research funds from: Abbvie, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Janssen/Johnson & Johnson, Leo Pharmaceuticals, Medimmune/Astra Zeneca, Novartis, Pfizer, Sciderm, Valeant, and ViDac. They are also a consultant for Allergan, Aqua, Boehringer-Ingelheim, LEO Pharma, Menlo, Mitsubishi, Promius and Theravance.

Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series

Information for

Open access

Opportunities

Help and information

Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series

Declaration of interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature